07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Achillion, J&J deal

Achillion granted Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion’s HCV assets. Achillion’s HCV pipeline includes ACH-3102 , a pan-genotypic, second-generation HCV NS5A protein inhibitor;...
07:00 , May 25, 2015 |  BioCentury  |  Strategy

You better you bet

Johnson & Johnson's deal with Achillion Pharmaceuticals Inc. ties up one of the last remaining and most advanced unpartnered HCV portfolios and gives the pharma what could be a best-in-class molecule to catch up in...
01:55 , May 20, 2015 |  BC Extra  |  Top Story

Achillion, Janssen partner to develop HCV combo

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) granted the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion's HCV assets. Achillion's HCV pipeline includes ACH-3102 , a...
01:50 , Feb 10, 2015 |  BC Extra  |  Top Story

Achillion climbs on ACH-3102 data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.84 to $11.66 on Monday after it said 100% of HCV genotype 1 patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR12 after six weeks...
04:11 , Dec 23, 2014 |  BC Extra  |  Clinical News

Achillion gains on HCV data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $1.28 to $15.49 on Monday after it said 100% of patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR4 after six weeks of treatment in...
03:26 , Oct 1, 2014 |  BC Extra  |  Top Story

J&J buying Alios for $1.75B

Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV). In July, the...
07:00 , Sep 1, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/29 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Deutsche Bank Robyn Karnauskas Upgrade Buy (from hold) 19% $11.57 Karnauskas also raised her...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

Sovaprevir: FDA hold

Achillion said FDA lifted a partial clinical hold on HCV compound sovaprevir. The company can now evaluate sovaprevir at a maximum dose of 200 mg once daily in HCV patients and in single dose trials...
07:00 , Jun 16, 2014 |  BioCentury  |  Finance

Hoping for a Cinderella moment

Investors flooded into Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) last week to get a piece of the lone biotech with unpartnered clinical-stage HCV assets. However, at least one buysider thinks Achillion missed its window of opportunity. Achillion...